medigraphic.com
ISSN 1027-2852 (Electronic)
ISSN 0864-4551 (Print)

2013, Number 2

<< Back

Biotecnol Apl 2013; 30 (2)

Transgenic plants of Nicotiana tabacum L. express aglycosylated monoclonal antibody with antitumor activity

Rodríguez M, Pujol M, Pérez L, Gavilondo JV, Garrido G, Ayala M, Pérez M, Bequet-Romero M, Cabrera G, Ramos O, Hernández I, González EM, Huerta V, Sánchez B, Mateo C, Triguero A, Mendoza O, Freyre F, Borroto C

Language: English
References: 15
Page: 157-161
PDF size: 270.31 Kb.


ABSTRACT

The expression and production of pharmaceutical, industrial and veterinary proteins in plants is an attractive approach. These expression hosts bear an enormous production potential in terms of volume, easy processing of the starting material, and safety of the final product due to the lack of pathogens able to infect animal and human cells. Antibodies are among the most frequently proteins expressed in plants, subsequently called plantibodies. However, plantibodies are differently glycosylated in plant cells, with oligosaccharide residues being added which may them immunogenic in the final organism. For that reason, several strategies have been developed to genetically modify host plants to mimic the N-glycosylation patterns typical in animal cells. This work was aimed at developing a strategy to obtain a aglycosylated plantibody version of nimotuzumab, the first antibody registered as a product in Cuba for cancer immunotherapy. The strategy comprised the genetic modification of the heavy chain glycosylation site of nimotuzumab, and its expression as an aglycosylated protein in tobacco leaves, by means of developing a transient expression system using Agrobacterium infiltration into tobacco leaves for the initial characterization of the plantibody. It was demonstrated that transgenic plants were capable of producing a plant-derived nimotuzumab antibody which retained the antitumor activity in vitro and in vivo, compared to its glycosylated counterpart produced in mammalian cells. This work demonstrates the potential of transgenic plants to produce aglycosylated therapeutic antibodies for cancer treatment, and won the National Award of the Academy of Sciences of Cuba in 2012.


REFERENCES

  1. Xu J, Dolan MC, Medrano G, Cramer CL, Weathers PJ. Green factory: plants as bioproduction platforms for recombinant proteins. Biotechnol Adv. 2012;30(5): 1171-84.

  2. Morandini F, Avesani L, Bortesi L, Van Droogenbroeck B, De Wilde K, Arcalis E, et al. Non-food/feed seeds as biofactories for the high-yield production of recombinant pharmaceuticals. Plant Biotechnol J. 2011;9(8):911-21.

  3. Borisjuk N, Komarnytsky S. Plantderived antibodies for academic, industrial, and therapeutic applications. In: Pathak Y, Benita S, editors. Antibody-mediated drug delivery systems: Concepts, technology, and applications. Hoboken: John Wiley and Sons, Inc.. 2012. p. 365-82.

  4. De Muynck B, Navarre C, Boutry M. Production of antibodies in plants: status after twenty years. Plant Biotechnol J. 2010;8(5):529-63.

  5. Petruccelli S, Otegui MS, Lareu F, Tran Dinh O, Fitchette AC, Circosta A, et al. A KDEL-tagged monoclonal antibody is efficiently retained in the endoplasmic reticulum in leaves, but is both partially secreted and sorted to protein storage vacuoles in seeds. Plant Biotechnol J. 2006; 4(5):511-27.

  6. Elvin JG, Couston RG, van der Walle CF. Therapeutic antibodies: market considerations, disease targets and bioprocessing. Int J Pharm. 2013;440(1):83-98.

  7. Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci. 2009;30(7):356-62.

  8. Hristodorov D, Fischer R, Joerissen H, Muller-Tiemann B, Apeler H, Linden L. Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies. Mol Biotechnol. 2013; 53(3):326-35.

  9. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Perez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology. 1997;3(1):71-81.

  10. Klein S, Levitzki A. Targeting the EGFR and the PKB pathway in cancer. Curr Opin Cell Biol. 2009;21(2):185-93.

  11. Perez R, Moreno E, Garrido G, Crombet T. EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects. Cancers. 2011;3(2):2014-31.

  12. Pujol M, Ramirez NI, Ayala M, Gavilondo JV, Valdes R, Rodriguez M, et al. An integral approach towards a practical application for a plant-made monoclonal antibody in vaccine purifi cation. Vaccine. 2005;23(15):1833-7.

  13. Rodriguez M, Ramirez NI, Ayala M, Freyre F, Perez L, Triguero A, et al. Transient expression in tobacco leaves of an aglycosylated recombinant antibody against the epidermal growth factor receptor. Biotechnol Bioeng. 2005;89(2):188-94.

  14. Rodriguez M, Perez L, Gavilondo JV, Garrido G, Bequet-Romero M, Hernandez I, et al. Comparative in vitro and experimental in vivo studies of the anti-epidermal growth factor receptor antibody nimotuzumab and its aglycosylated form produced in transgenic tobacco plants. Plant Biotechnol. J. 2013;11(1):53-65.

  15. Pujol M, Gavilondo J, Ayala M, Rodriguez M, Gonzalez EM, Perez L. Fighting cancer with plant-expressed pharmaceuticals. Trends Biotechnol. 2007;25(10):455-9.




2020     |     www.medigraphic.com